lurasidone CAS NO.367514-87-2

Anhui Haikang Pharmaceutical Co.,
Ltd. is a collection of scientific
research,production and sales
High-Tech Enterprise,which
established in 2009,and covers an
area of 28,000 ㎡.Company locates
in Anqing city,on the bond of
Yangtze River, invested 80 million
RMB to set up synthesis workshops
and clean workshops.All the
productions strictly conform to GMP
standard and equipped with
high-class R&D center.The first
branch was founded in 2010,called
Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.
Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.
To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Lurasidone(SM-13496)isanantagonistofdopamineD2and5-HT7withIC50sof1.68±0.09and0.495±0.090nM,respectively.Lurasidone(SM-13496)isalsoapartialagonistof5-HT1AreceptorwithanIC50of6.75±0.97nM.InvitroreceptorbindingexperimentsrevealthatLurasidone(SM-13496)demonstratesaffinityfordopaChemicalbookmineD2and5-HT2Areceptorshigherthanothertestedantipsychotics.Lurasidone(SM-13496)doesnotincrease[35S]GTPγSbindingtothemembranepreparationsfordopamineD2receptorsbyitself,butitantagonizesdopamine-stimulated[35S]GTPγSbindinginaconcentration-dependentmannerwithaKBvalueof2.8±1.1nM.

Lurasidone is an atypical antipsychotic drug developed by Japan's DainipponSumitomo Pharmaceutical Company. It belongs to the 3.1 category of chemical drug registration and is suitable for the treatment of patients with schizophrenia. The efficacy was determined in four 6-week controlled studies in adult patients with schizophrenia. The exact mechanism of its treatment of schizophrenia is still unclear like other atypical antipsychotics, and may be related to the antagonism of dopamine D2 and serotonin 2A (5-HT2A) receptors. It is used in the treatment of schizophrenia, and studies have reported that lurasidone can improve cognitive function. On October 28, 2010, the United States FChemicalbookDA approved lurasidone hydrochloride (lurasidoneHCI) once a day tablets for the first-line treatment of patients with schizophrenia, and its trade name is Latuda. Usage and dosage: The recommended starting dose is 40mg·d, the effective dose range is 40～120mg·d, and the maximum recommended dose is 80mg·d. It should be taken with food. Adverse reactions: Common adverse reactions include drowsiness, akathisia, nausea, Parkinson's disease-like symptoms, and emotional anxiety. Lurasidone has no physical dependence, causes less weight gain, and does not cause changes in glucose, lipids (lipids), ECG and QT intervals.